Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Daniela Russo
Observed names:
D. Russo,
Russo, Daniela
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institutions:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Fondazione IRCCS Istituto Nazionale dei Tumori
ORCID:
0000-0001-9471-1935
Observed ORCID:
0000-0001-9471-1935
OpenAlex ID:
A5079704027
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study
2016
·
Marina Bagnoli
, Silvana Canevari
, et al.
·
The Lancet Oncology
·
128
PDF
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
2020
·
Lucia Musacchio
, Giuseppe Caruso
, et al.
·
Cancer Management and Research
·
52
PDF
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
2022
·
E.D. Capoluongo
, B. Pellegrino
, et al.
·
ESMO Open
·
48
PDF
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
2024
·
S. Pignata
, D. Califano
, et al.
·
Annals of Oncology
·
41
PDF
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)
2022
·
Lucia Musacchio
, Daniela Califano
, et al.
·
British Journal of Cancer
·
29
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study
2021
·
Daniela Califano
, Daniela Gallo
, et al.
·
Cancers
·
25
PDF
Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience
2020
·
Daniela Califano
, Daniela Russo
, et al.
·
Cells
·
15
PDF
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial
2025
·
B. Pellegrino
, E.D. Capoluongo
, et al.
·
ESMO Open
·
14
From Clinical Trials to Clinical Use of Checkpoint Inhibitors for Patients With Metastatic Urothelial Cancer
2020
·
Rosa Tambaro
, Marilena Di Napoli
, et al.
·
Immunotherapy
·
14
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients
2022
·
Crescenzo D’Alterio
, Anna Spina
, et al.
·
Cancers
·
13
PDF
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial
2023
·
Luca Forlani
, Loris De Cecco
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
9
PDF
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab
2022
·
Marina Fabbi
, Delfina Costa
, et al.
·
Diagnostics
·
8
PDF
CBX7 Expression in Oncocytic Thyroid Neoplastic Lesions (Hürthle Cell Adenomas and Carcinomas)
2014
·
Mario Monaco
, Gennaro Chiappetta
, et al.
·
European Thyroid Journal
·
7
PDF
The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells
2024
·
Daniela Russo
, Anna Spina
, et al.
·
PLoS ONE
·
6
PDF
Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy
2020
·
Jole Ventriglia
, Immacolata Paciolla
, et al.
·
International Journal of Gynecological Cancer
·
5
Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial
2025
·
Eliana Pivetta
, Vincenzo Canzonieri
, et al.
·
npj Precision Oncology
·
4
PDF
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial)
2025
·
C. D’Alterio
, G. Rea
, et al.
·
Cancer Immunology Immunotherapy
·
4
PDF
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial
2025
·
M. Bartoletti
, A. Passarelli
, et al.
·
ESMO Open
·
3
PDF
Impact of metabolism-related markers on outcomes in ovarian cancer patients: Findings of the MITO16A/MaNGO-OV2 trial
2024
·
Stefano Indraccolo
, Simona Signoriello
, et al.
·
The International Journal of Biological Markers
·
3
TP53 mutations and survival in ovarian carcinoma patients receiving first‐line chemotherapy plus bevacizumab: Results of the MITO16A / MaNGO OV ‐2 study
2024
·
Eliana Bignotti
, Vittorio Simeon
, et al.
·
International Journal of Cancer
·
3
PDF
Programmed death‐ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV‐2 translational study
2025
·
Francesca Basso‐Valentina
, Vincenzo Canzonieri
, et al.
·
Clinical and Translational Medicine
·
2
PDF
MITO END-3: efficacy of Avelumab immunotherapy according to molecular profiling in first line endometrial cancer therapy
2023
·
Sandro Pignata
, Daniela Califano
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
·
1
A case of anaplastic diffuse large B-cell thyroid lymphoma: Unique immunophenotype and unusual clinical presentation
2010
·
R. Bruno
, P. Giannasio
, et al.
·
Journal of Endocrinological Investigation
·
1
PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study
2026
·
Anna Passarelli
, Giovanni Luca Scaglione
, et al.
·
JCO Precision Oncology
PDF
Somatic BRCA1 and BRCA2 detection in homologous recombination deficiency testing: concordance of four sequencing workflows with the Myriad myChoice companion diagnostic
2026
·
Giovanni Luca Scaglione
, Cristin Roma
, et al.
·
International Journal of Gynecological Cancer
Show more works
View as search
Works count:
32
Citation count:
435
H-index:
10
I10-index:
10
Year
Topic
Type